B · Normal
[Bayer’s Sevainitib Tablets Approved in China as First-Line Treatment for HER2-mutated Non-Small Cell Lung Cancer] On November 4, Bayer China announced that the National Medical Products Administration has approved the new targeted lung cancer drug Hersino® (sevainitib tablets) as a single agent for the treatment of adult patients with unresectable locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating mutations of HER2 (ERBB2).
medicine 🕐 2026-11-04 16:24
#bayer #cell #medicine
Save as Image Generate a beautiful long image to share on Moments or in group chats Generate now ⬇
← Back to Telegraph

Related telegraphs

[Study finds that regulating fatty acid metabolism may help clear senescent cell 11-04 18:12 [Beijing-Hong Kong Fair signed commercial aerospace and other 47 projects worth 11-04 17:17 [Sino Biopharmaceuticals and Boehringer Ingelheim reached a US$7 billion coopera 11-04 17:00 [The most detailed map revealing the impact of genetic variation on the immune s 11-04 06:55 [The Private Bureau of the National Development and Reform Commission publicly p 11-03 19:48 [Pfizer Pharmaceuticals raises full-year adjusted earnings per share forecast] N 11-03 19:46

Comments

0/500
Captcha (click to refresh)
No comments yet